drugset / Trial / NCT02256969

Intraductal Meibomian Gland Probing Trial

NCT02256969

Phase 4 Completed 45 enrolled Joseph B. Ciolino, MD
RandomizedParallel-groupDouble-blindTreatment

Summary

In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or their symptoms. The investigators are also evaluating the effects of using two (2) post-procedural medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after the MGP procedure has an effect on its outcome.

Timeline

Start
2014-10
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject GenTeal PM Night-Time Unknown Topical
Comparator Prednisolone Other / unclassified Topical
Comparator Sulfacetamide Small molecule Topical

Indications